Twenty-five years ago this month, the New England Journal of Medicine published a special report on something that’s become medical gospel:

Aspirin.

That’s right. Not as in “take two and call me in the morning,” but in the realm of the randomized double-blinded placebo-controlled trial. Or what we generally consider the gold standard of evidence in medical research.

If you’ve often heard that bit of jargon but always wondered why it’s so exalted, break it down:

  • randomized: the assignment of the treatment (aspirin) or placebo (‘inert’ sugar pill) is not given in any planned sequence.
  • double-blinded: neither the researchers nor the subjects know who is taking what (everything is coded so that analysts can find out at the end).
  • placebo-controlled: the study compares the treatment against placebo to see if it’s helpful or harmful.

Even though acetylsalicylic acid’s properties as a pain reliever and fever reducer had been known in the time of Hippocrates, it was in 1899 that Bayer first patented and marketed what came to be known as aspirin worldwide.

A mere 89 years later, researchers from the “Physicians Health Study” did something unusual. Citing aspirin’s “extreme beneficial effects on non-fatal and fatal myocardial infarction”–doctor speak for heart attacks–the study’s Data Monitoring Board recommended terminating the aspirin portion of the study early (the study also was looking at the effects of beta-carotene). In other words, the benefit in preventing heart attacks was so clear at 5 years instead of the planned 12 years of study that it was deemed unethical to continue blinding participants or using placebo.

Turns out that aspirin inhibits platelets, tiny specialized blood cells whose job it is to stop your cuts from bleeding. In heart attacks, platelets clump inside the arteries of the heart depriving the heart muscle of vital oxygen. Using aspirin to inhibit their function is a key mechanism of preventing this phenomenon.

The amazing thing is that it took decades to organize an elegant and simple enough study with enough power (statistical heft) to show that good ol’ aspirin could really make a difference.

And that it was “just” aspirin. Shows how far we have yet to go in building medical knowledge.

John H. Schumann, MD is a general internist and medical educator at the University of Oklahoma School of Community Medicine in Tulsa, OK . He is also author of the blog, GlassHospital (@GlassHospital), where this post originally appeared.

Share on FacebookTweet about this on TwitterShare on Google+Share on LinkedIn

5 Responses for “What the Story of a Famous Little White Pill Says About How Medical Research Works”

  1. Curly Harrison, MD says:

    This study had and continues to have far reaching impact. The evidence is solid. Aspirin is cheap, safe, effective, usable, and prevents heart attacks.

    What is the evidence that CPOE and EHR devices are safe, effective, usable, and improve outcomes and prevent adverse events? Hmmm, they are not cheap.

    Aspirin appears to be orders of magnitude more cost effective than these government mandated devices that are being deployed in an unregulated experiment.

  2. Doug says:

    I think that we may be surprised at a number of possible other uses for many drugs that have been developed. Each year millions of dollars are spent developing one particular cure that is rejected by the FDA as it may not necessarily address its intended ailment, yet could potentially help with another. Looking forward to seeing what lies ahead in the decades to come.

  3. Arthur says:

    Wow, this is incredible piece of information. A simple drug like Aspirin can be used to treat heart attacks is really mind blowing. Over the time, lot of money has been put into development and research of medicines which help prevent heart attack when the solution was lying just before our eyes.

    I think there has to be a extended study on this and a detailed report on the side effects discussed thoroughly and implement the use of Aspirin for heart diseases.

    This should be a very helpful solution for a lot of poor patients who have no money to treat heart diseases

Leave a Reply

MASTHEAD STUFF

MATTHEW HOLT
Founder & Publisher

JOHN IRVINE
Executive Editor

MUNIA MITRA, MD
Editor, Business of Healthcare

JOE FLOWER
Contributing Editor

MICHAEL MILLENSON
Contributing Editor

MICHELLE NOTEBOOM
Business Development

VIKRAM KHANNA
Editor-At-Large, Wellness

ALINE NOIZET
Editor-At-Large, Europe
THCB FROM A-Z

FOLLOW US ON TWITTER
@THCBStaff

WHERE IN THE WORLD WE ARE

The Health Care Blog (THCB) is based in San Francisco. We were founded in 2003 by Matthew Holt. John Irvine joined a year later and now runs the site.

MEDIA REQUESTS

Interview Requests + Bookings. We like to talk. E-mail us.

BLOGGING
Yes. We're looking for bloggers. Send us your posts.

STORY TIPS
Breaking health care story? Drop us an e-mail.

CROSSPOSTS

We frequently accept crossposts from smaller blogs and major U.S. and International publications. You'll need syndication rights. Email a link to your submission.

WHAT WE'RE LOOKING FOR

Op-eds. Crossposts. Columns. Great ideas for improving the health care system. Pitches for healthcare-focused startups and business.Write ups of original research. Reviews of new healthcare products and startups. Data-driven analysis of health care trends. Policy proposals. E-mail us a copy of your piece in the body of your email or as a Google Doc. No phone calls please!

THCB PRESS

Healthcare focused e-books and videos for distribution via THCB and other channels like Amazon and Smashwords. Want to get involved? Send us a note telling us what you have in mind. Proposals should be no more than one page in length.

HEALTH SYSTEM $#@!!!
If you've healthcare professional or consumer and have had a recent experience with the U.S. health care system, either for good or bad, that you want the world to know about, tell us about it. Have a good health care story you think we should know about? Send story ideas and tips to editor@thehealthcareblog.com.

REPRINTS Questions on reprints, permissions and syndication to ad_sales@thehealthcareblog.com.

WHAT WE COVER

HEALTHCARE, GENERAL

Affordable Care Act
Business of Health Care
National health policy
Life on the front lines
Practice management
Hospital managment
Health plans
Prevention
Specialty practice
Oncology
Cardiology
Geriatrics
ENT
Emergency Medicine
Radiology
Nursing
Quality, Costs
Residency
Research
Medical education
Med School
CMS
CDC
HHS
FDA
Public Health
Wellness

HIT TOPICS
Apple
Analytics
athenahealth
Electronic medical records
EPIC
Design
Accountable care organizations
Meaningful use
Interoperability
Online Communities
Open Source
Privacy
Usability
Samsung
Social media
Tips and Tricks
Wearables
Workflow
Exchanges

EVENTS

Health 2.0
TedMed
HIMSS
SXSW
WHCC
AHIP
Log in - Powered by WordPress.